Market Analysis — MASSACHUSETTS EYE AND EAR INFIRMARY
MA market | 19 hospitals | HHI: nan (Competitive)
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
19
Hospitals in Market
5,898
Total Beds
$15.2B
Market Revenue
Competitive
HHI: nan
None
Moat Rating (2/10)
#10
Market Share Rank
Competitive Moat (Mauboussin Framework)
Based on "Measuring the Moat" adapted for healthcare. Score 0-10: wide (8+), narrow (5-7), none (<5).
Scale Advantageweak
Switching Costslow
Market Share1.7%
Top 3 Concentration53.8%
Network Density0.32
Margin vs Market+27.6%
Bed Util vs Market-31.2%
What This Means
This hospital has a none moat — no moat — commoditized market position, pricing power limited. The MA market is competitive — many players, value creation must come from operations not market power (HHI: nan).
Implications: Operational improvements are the primary value driver — see the EBITDA bridge. Compare against peers via comparables or see the full MA market.
Top Competitors
| Hospital | Beds | Revenue | Rev Share | Bed Share |
|---|---|---|---|---|
| MASSACHUSETTS GENERAL HOSPITAL | 997 | $3,504M | 23.0% | 16.9% |
| BRIGHAM AND WOMENS HOSPITAL | 812 | $2,799M | 18.4% | 13.8% |
| DANA-FARBER CANCER INSTITUTE | 30 | $1,884M | 12.4% | 0.5% |
| BETH ISRAEL DEACONESS MEDICAL CENTER | 705 | $1,674M | 11.0% | 11.9% |
| CHILDRENS HOSPITAL CORPORATION | 485 | $1,586M | 10.4% | 8.2% |
| BOSTON MEDICAL CENTER | 440 | $1,194M | 7.8% | 7.5% |
| TUFTS MEDICAL CENTER | 385 | $820M | 5.4% | 6.5% |
| STEWARD ST. ELIZABETHS MEDICAL CTR | 244 | $429M | 2.8% | 4.1% |
| FAULKNER HOSPITAL | 147 | $317M | 2.1% | 2.5% |
| NEW ENGLAND BAPTIST HOSPITAL | 75 | $221M | 1.5% | 1.3% |
Regional Payer Mix
■ Medicare 25%■ Medicaid 22%■ Commercial 53%